Current update on cytogenetics, taxonomy, diagnosis, and management of adrenocortical carcinoma: What radiologists should know

American Journal of Roentgenology

Volumn 199, Issue 6, 2012, Pages 1283-1293

  Ganeshan, Dhakshina ^a   Bhosale, Priya ^a   Kundra, Vikas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adrenocortical carcinoma; CT; FDG PET CT; MRI

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUORINE 18; MITOTANE; PROTEIN P53; SOMATOMEDIN B; STREPTOZOCIN;

ADRENAL CORTEX CARCINOMA; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOGENETICS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; ECHOGRAPHY; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; IMAGING SYSTEM; INSULIN LIKE GROWTH FACTOR II GENE; MOLECULAR PATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; CYTOGENETIC ANALYSIS; DIAGNOSTIC IMAGING; HUMANS; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 84870866055     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.8282     Document Type: Review

References (102)

1. Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 2009; 23:273-289
2. Libè R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007; 14:13-28 (Pubitemid 47521719)
3. Michalkiewicz E, Sandrini R, Figueiredo B, et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol 2004; 22:838-845 (Pubitemid 41103595)
4. Didolkar MS, Bescher RA, Elias EG, Moore RH. Natural history of adrenal cortical carcinoma: a clinicopathologic study of 42 patients. Cancer 1981; 47:2153-2161 (Pubitemid 11098583)
5. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990; 322:1195-1201 (Pubitemid 20137851)
6. Søreide JA, Brabrand K, Thoresen SO. Adrenal cortical carcinoma in Norway, 1970-1984. World J Surg 1992; 16:663-667; discussion, 668
7. Hutter AM Jr, Kayhoe DE. Adrenal cortical carcinoma: results of treatment with o,p'DDD in 138 patients. Am J Med 1966; 41:581-592
8. Bertherat J, Bertagna X. Pathogenesis of adrenocortical cancer. Best Pract Res Clin Endocrinol Metab 2009; 23:261-271
9. Sandrini R, Ribeiro RC, DeLacerda L. Childhood adrenocortical tumors. J Clin Endocrinol Metab 1997; 82:2027-2031
10. Kasperlik-Zaluska AA, Roslonowska E, Slowinska- Srzednicka J, et al. Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients. Clin Endocrinol (Oxf) 1997; 46:29-37 (Pubitemid 27072843)
11. Zini L, Porpiglia F, Fassnacht M. Contemporary management of adrenocortical carcinoma. Eur Urol 2011; 60:1055-1065
12. Barzon L, Boscaro M. Diagnosis and management of adrenal incidentalomas. J Urol 2000; 163:398-407 (Pubitemid 30060481)
13. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 2004; 25:309-340 (Pubitemid 38528713)
14. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85:637-644
15. Barnett CC Jr, Varma DG, El-Naggar AK, et al. Limitations of size as a criterion in the evaluation of adrenal tumors. Surgery 2000; 128:973-982; discussion, 982-973
16. Favia G, Lumachi F, Basso S, D'Amico DF. Management of incidentally discovered adrenal masses and risk of malignancy. Surgery 2000; 128:918-924
17. Lloyd RVTA, Kimura N, McNichol AM, Young WF Jr. Tumours of the adrenal gland. In: DeLellis RALR, Heitz PU, Eng C, eds. World Health Organization classification of tumours: pathology and genetics of tumours of endocrine organs. Lyon, France: IARC Press, 2004:135-174
18. Hoang MP, Ayala AG, Albores-Saavedra J. Oncocytic adrenocortical carcinoma: a morphologic, immunohistochemical and ultrastructural study of four cases. Mod Pathol 2002; 15:973-978
19. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989; 13:202-206 (Pubitemid 19081702)
20. Blake MA, Cronin CG, Boland GW. Adrenal imaging. AJR 2010; 194:1450-1460
21. Hough AJ, Hollifield JW, Page DL, Hartmann WH. Prognostic factors in adrenal cortical tumors: a mathematical analysis of clinical and morphologic data. Am J Clin Pathol 1979; 72:390-399 (Pubitemid 10231372)
22. van Slooten H, Schaberg A, Smeenk D, Moolenaar AJ. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer 1985; 55:766-773 (Pubitemid 15173514)
23. McNicol AM. Lesions of the adrenal cortex. Arch Pathol Lab Med 2008; 132:1263-1271
24. Harrison LE, Gaudin PB, Brennan MF. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 1999; 134:181-185 (Pubitemid 29088971)
25. Tissier F. Classification of adrenal cortical tumors: what limits for the pathological approach? Best Pract Res Clin Endocrinol Metab 2010; 24:877-885
26. Giordano TJ. Classification of adrenal cortical tumors: promise of the 'molecular' approach. Best Pract Res Clin Endocrinol Metab 2010; 24:887-892
27. Libè R, Bertherat J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur J Endocrinol 2005; 153:477-487 (Pubitemid 41568145)
28. Dohna M, Reincke M, Mincheva A, Allolio B, Solinas-Toldo S, Lichter P. Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes Cancer 2000; 28:145-152 (Pubitemid 30246992)
29. Gicquel C, Bertagna X, Gaston V, et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 2001; 61:6762-6767 (Pubitemid 32896498)
30. Soon PS, Sidhu SB. Molecular basis of adrenocortical carcinomas. Minerva Endocrinol 2009; 34:137-147
31. Opocher G, Schiavi F, Cicala MV, et al. Genetics of adrenal tumors. Minerva Endocrinol 2009; 34:107-121
32. Yano T, Linehan M, Anglard P, et al. Genetic changes in human adrenocortical carcinomas. J Natl Cancer Inst 1989; 81:518-523 (Pubitemid 19102220)
33. Herbet M, Feige JJ, Thomas M. Insights into the role of genetic alterations in adrenocortical tumorigenesis. Mol Cell Endocrinol 2009; 300:169-174
34. de Reyniès A, Assie G, Rickman DS, et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 2009; 27:1108-1115
35. Giordano TJ, Kuick R, Else T, et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 2009; 15:668-676
36. Libè R, Groussin L, Tissier F, et al. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res 2007; 13:844-850 (Pubitemid 46340358)
37. Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 2005; 12:667-680 (Pubitemid 41483000)
38. Hamper UM, Fishman EK, Hartman DS, Roberts JL, Sanders RC. Primary adrenocortical carcinoma: sonographic evaluation with clinical and pathologic correlation in 26 patients. AJR 1987; 148:915-919 (Pubitemid 17068849)
39. Korobkin M, Giordano TJ, Brodeur FJ, et al. Adrenal adenomas: relationship between histologic lipid and CT and MR findings. Radiology 1996; 200:743-747 (Pubitemid 26282274)
40. Lee MJ, Hahn PF, Papanicolaou N, et al. Benign and malignant adrenal masses: CT distinction with attenuation coefficients, size, and observer analysis. Radiology 1991; 179:415-418
41. Caoili EM, Korobkin M, Francis IR, et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 2002; 222:629-633 (Pubitemid 34215205)
42. Hahn PF, Blake MA, Boland GW. Adrenal lesions: attenuation measurement differences between CT scanners. Radiology 2006; 240:458-463 (Pubitemid 44098642)
43. Korobkin M. CT characterization of adrenal masses: the time has come. Radiology 2000; 217:629-632
44. Peña CS, Boland GW, Hahn PF, Lee MJ, Mueller PR. Characterization of indeterminate (lipidpoor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology 2000; 217:798-802
45. Boland GW, Hahn PF, Pena C, Mueller PR. Adrenal masses: characterization with delayed contrast-enhanced CT. Radiology 1997; 202:693-696 (Pubitemid 27093439)
46. Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR 1998; 171:201-204 (Pubitemid 28308675)
47. Caoili EM, Korobkin M, Francis IR, Cohan RH, Dunnick NR. Delayed enhanced CT of lipid-poor adrenal adenomas. AJR 2000; 175:1411-1415
48. Kamiyama T, Fukukura Y, Yoneyama T, Takumi K, Nakajo M. Distinguishing adrenal adenomas from nonadenomas: combined use of diagnostic parameters of unenhanced and short 5-minute dynamic enhanced CT protocol. Radiology 2009; 250:474-481
49. Blake MA, Kalra MK, Sweeney AT, et al. Distinguishing benign from malignant adrenal masses: multi-detector row CT protocol with 10-minute delay. Radiology 2006; 238:578-585 (Pubitemid 43134370)
50. Young WF Jr. The incidentally discovered adrenal mass. N Engl J Med 2007; 356:601-610
51. Johnson PT, Horton KM, Fishman EK. Adrenal mass imaging with multidetector CT: pathologic conditions, pearls, and pitfalls. RadioGraphics 2009; 29:1333-1351
52. Kenney PJ, Wagner BJ, Rao P, Heffess CS. Myelolipoma: CT and pathologic features. Radiology 1998; 208:87-95 (Pubitemid 28323314)
53. Egbert N, Elsayes KM, Azar S, Caoili EM. Computed tomography of adrenocortical carcinoma containing macroscopic fat. Cancer Imaging 2010; 10:198-200
54. Patel VG, Babalola OA, Fortson JK, Weaver WL. Adrenal myelolipoma: report of a case and review of the literature. Am Surg 2006; 72:649-654 (Pubitemid 46940728)
55. Dunnick NR. Adrenal carcinoma. Radiol Clin North Am 1994; 32:99-108 (Pubitemid 24053275)
56. Johnson PT, Horton KM, Fishman EK. Adrenal imaging with multidetector CT: evidence-based protocol optimization and interpretative practice. RadioGraphics 2009; 29:1319-1331
57. Bharwani N, Rockall AG, Sahdev A, et al. Adrenocortical carcinoma: the range of appearances on CT and MRI. AJR 2011; 196:1298; [web] W706-W714
58. Hricak H, Amparo E, Fisher MR, Crooks L, Higgins CB. Abdominal venous system: assessment using MR. Radiology 1985; 156:415-422 (Pubitemid 15029775)
59. Schlund JF, Kenney PJ, Brown ED, Ascher SM, Brown JJ, Semelka RC. Adrenocortical carcinoma: MR imaging appearance with current techniques. J Magn Reson Imaging 1995; 5:171-174
60. Goldfarb DA, Novick AC, Lorig R, et al. Magnetic resonance imaging for assessment of vena caval tumor thrombi: a comparative study with venacavography and computerized tomography scanning. J Urol 1990; 144:1100-1103; discussion, 1103-1104
61. Hallscheidt PJ, Fink C, Haferkamp A, et al. Preoperative staging of renal cell carcinoma with inferior vena cava thrombus using multidetector CT and MRI: prospective study with histopathological correlation. J Comput Assist Tomogr 2005; 29:64-68 (Pubitemid 40194440)
62. Guzzo TJ, Pierorazio PM, Schaeffer EM, Fishman EK, Allaf ME. The accuracy of multidetector computerized tomography for evaluating tumor thrombus in patients with renal cell carcinoma. J Urol 2009; 181:486-490; discussion, 491
63. Lawrentschuk N, Gani J, Riordan R, Esler S, Bolton DM. Multidetector computed tomography vs magnetic resonance imaging for defining the upper limit of tumour thrombus in renal cell carcinoma: a study and review. BJU Int 2005; 96:291-295 (Pubitemid 41097668)
64. Halefoglu AM, Yasar A, Bas N, Ozel A, Erturk SM, Basak M. Comparison of computed tomography histogram analysis and chemical-shift magnetic resonance imaging for adrenal mass characterization. Acta Radiol 2009; 50:1071-1079
65. Jhaveri KS, Wong F, Ghai S, Haider MA. Comparison of CT histogram analysis and chemical shift MRI in the characterization of indeterminate adrenal nodules. AJR 2006; 187:1303-1308 (Pubitemid 44630836)
66. Israel GM, Korobkin M, Wang C, Hecht EN, Krinsky GA. Comparison of unenhanced CT and chemical shift MRI in evaluating lipid-rich adrenal adenomas. AJR 2004; 183:215-219 (Pubitemid 38789040)
67. Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer 2007; 14:587-599 (Pubitemid 350074049)
68. Szolar DH, Korobkin M, Reittner P, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology 2005; 234:479-485 (Pubitemid 40139919)
69. Ferrozzi F, Bova D. CT and MR demonstration of fat within an adrenal cortical carcinoma. Abdom Imaging 1995; 20:272-274
70. Heye S, Woestenborghs H, Van Kerkhove F, Oyen R. Adrenocortical carcinoma with fat inclusion: case report. Abdom Imaging 2005; 30:641-643 (Pubitemid 41446686)
71. Zhang HM, Perrier ND, Grubbs EG, et al. CT features and quantification of the characteristics of adrenocortical carcinomas on unenhanced and contrast- enhanced studies. Clin Radiol 2012; 67:38-46
72. Faria JF, Goldman SM, Szejnfeld J, et al. Adrenal masses: characterization with in vivo proton MR spectroscopy - initial experience. Radiology 2007; 245:788-797 (Pubitemid 350127349)
73. Burtscher IM, Holtas S. Proton MR spectroscopy in clinical routine. J Magn Reson Imaging 2001; 13:560-567 (Pubitemid 32231510)
74. Mullins ME. MR spectroscopy: truly molecular imaging; past, present and future. Neuroimaging Clin N Am 2006; 16:605-618 [viii] (Pubitemid 44828757)
75. Elaini AB, Shetty SK, Chapman VM, et al. Improved detection and characterization of adrenal disease with PET-CT. RadioGraphics 2007; 27:755-767
76. Chong S, Lee KS, Kim HY, et al. Integrated PETCT for the characterization of adrenal gland lesions in cancer patients: diagnostic efficacy and interpretation pitfalls. RadioGraphics 2006; 26:1811-1824; discussion, 1824-1816 [Erratum in Radio-Graphics 2007; 27:1594]
77. Boland GW, Dwamena BA, Jagtiani Sangwaiya M, et al. Characterization of adrenal masses by using FDG PET: a systematic review and metaanalysis of diagnostic test performance. Radiology 2011; 259:117-126
78. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 2001; 42:1795-1799
79. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med 2004; 45:2058-2062
80. Okada M, Shimono T, Komeya Y, et al. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions. Ann Nucl Med 2009; 23:349-354
81. 18F- Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J Clin Endocrinol Metab 2009; 94:1713-1722
82. Leboulleux S, Dromain C, Bonniaud G, et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adreno cortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 2006; 91:920-925 (Pubitemid 43357759)
83. Lacroix A. Approach to the patient with adrenocortical carcinoma. J Clin Endocrinol Metab 2010; 95:4812-4822
84. Fassnacht M, Libè R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol 2011; 7:323-335
85. Balasubramaniam S, Fojo T. Practical considerations in the evaluation and management of adrenocortical cancer. Semin Oncol 2010; 37:619-626
86. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2008; 35:725-733
87. 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med 2009; 50:1448-1454
88. 123I-meta- iodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf) 2008; 69:181-188
89. Mody MK, Kazerooni EA, Korobkin M. Percutaneous CT-guided biopsy of adrenal masses: immediate and delayed complications. J Comput Assist Tomogr 1995; 19:434-439
90. Habscheid W, Pfeiffer M, Demmrich J, Muller HA. Puncture track metastasis after ultrasound-guided fine-needle puncture biopsy: a rare complication? [in German]. Dtsch Med Wochenschr 1990; 115:212-215 (Pubitemid 20039292)
91. Mazzaglia PJ, Monchik JM. Limited value of adrenal biopsy in the evaluation of adrenal neoplasm: a decade of experience. Arch Surg 2009; 144:465-470
92. Gruschwitz T, Breza J, Wunderlich H, Junker K. Improvement of histopathological classification of adrenal gland tumors by genetic differentiation. World J Urol 2010; 28:329-334
93. Miller BS, Ammori JB, Gauger PG, Broome JT, Hammer GD, Doherty GM. Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg 2010; 34:1380-1385
94. Gonzalez RJ, Shapiro S, Sarlis N, et al. Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery 2005; 138:1078-1085; discussion, 1085-1076
95. Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma - clinical update. J Clin Endocrinol Metab 2006; 91:2027-2037 (Pubitemid 43854976)
96. Norton J. Adrenal tumors. In: DeVita VTSH, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia, PA: Lippincott Williams & Wilkins, 2005:1528-1539
97. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007; 356:2372-2380 (Pubitemid 46883771)
98. Sabolch A, Feng M, Griffith K, Hammer G, Doherty G, Ben-Josef E. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys 2011; 80:1477-1484
99. Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 2005; 12:657-666 (Pubitemid 41482999)
100. Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 2001; 25:891-897 (Pubitemid 32666390)
101. Kebebew E, Reiff E, Duh QY, Clark OH, Mc-Millan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg 2006; 30:872-878 (Pubitemid 43724119)
102. Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 2008; 113:3130-3136